Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Elenbecestat

- PMLiVE

Bio investors react as Clinton tweet pledges pricing crackdown

Pharma companies come under scrutiny for pricing policies

Biogen’s Douglas Williams departs for biotech start-up

Research head will be first member of a new cancer-focused firm

- PMLiVE

Glimmer of hope for amyloid drugs in Alzheimer’s?

Expectations remain high but high efficacy rates still allusive for most firms

EISAI

Eisai to transfer US manufacturing campus to Biogen

Willhand over Research Triangle Park facility incapacity-sharing deal

- PMLiVE

AbbVie and C2N take tau antibody into clinic

Treatment being assessed for a progressive neurodegenerative disorder

- PMLiVE

Roche and Evotec’s Alzheimer’s drug ineffective

Sembragiline failed to show cognitive and memory benefits

EISAI

Eisai launches thyroid cancer therapy Lenvima in UK

The UK is its first European market, with wider EU roll out expected in coming months

- PMLiVE

Disappointment for pharma with new Cancer Drugs Fund list

Bayer the only firm to win a reprieve from the CDF drug cull

EISAI

Eisai to share clinical trial data via external website

Company aims to further promote transparency in the industry

Biogen promotes Matt Griffiths to chief information officer

He originally joined the firm from Dell earlier this year

- PMLiVE

Pfizer maintains lead in top CNS drug sales – just

But Biogen is looking to take the top spot next year as its MS portfolio grows

National Institute for Health and Care Excellence NICE logo

UK market access issues put on hold during election

NICE appraisals and Cancer Drugs Fund appeals will not be undertaken until May

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links